PHARMASPIRE - Volume 13, Issue 3, July - September, 2021

Pages: 114-116

Date of Publication: 07-Jun-2022

Print Article   Download XML  Download PDF

Existing therapies of coronavirus disease-2019 treatment under consideration: A technical note

Author: Dilpreet Singh

Category: Pharmaceutics

Abstract:

Coronavirus disease-2019 (COVID-19) is a pandemic outbreak in the world and is the leading cause of severe acute respiratory syndrome. At present, no new drug that selectively used for COVID-19 treatment is available. Existing drugs with alternative mechanism of action found beneficial and show faster recovery rate in COVID-19 patients. Drugs with anti-malarial, anti-arthritic, anti-hypertensive, anti-cancer, and immunomodulatory activity found useful in COVID-19. However, usage of these drugs is limited due to lack of clinical trials and safety. In this review, we discussed brief overview of existing treatment of COVID-19.

Keywords: Coronavirus diease-2019, existing drugs, severe acute respiratory syndrome, new drug application, efficacy

References:

1. Van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, et al. Identification of a new human coronavirus. Nat Med 2004;10:368-73.

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

3. Holmes KV. SARS-associated coronavirus. N Engl J Med 2003;348:1948-51.

4. DiMasi JA. A new look at united states drug development and approval times. Am J Ther 1996;3:647-57.

5. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabet Metab Synd Clin Res Rev 2020;14:241-6.

6. Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949.

7. Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: The need for an evidence base. Lancet Respir Med 2020;8:539-41.

8. Jin L, Feng X, Rong H, Pan Z, Inaba Y, Qiu L, et al. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun 2013;4:1-8.

9. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:104787.

10. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation 2020;141:1648-55.

11. Clinical Trials on Losartan. Available from: https://www.clinicaltrials.gov/ ct2/show/NCT04335123. [Last accessed on 2020 May 04].

12. Faujdar J, Gupta P, Natrajan M, Das R, Chauhan DS, Katoch VM, et al. Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis. Indian J Med Res 2011;134:696.

13. Chen WH, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: An overview. Curr Trop Med Rep 2020;2020:1-4.

14. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4.

15. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 2020;18:1-5.

16. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv 2020;2020:3.

17. Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, et al. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 pneumonia. Preprints 2020;2020:2039